[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636076":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":30,"centralContacts":35,"locations":40,"responsibleParty":69,"collaborators":10,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":10,"studyType":86,"phases":10,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":58,"whyStopped":10,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Università Vita-Salute San Raffaele","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients > 18 years and \u003C75 years with advanced heart failure",null,"1. Age \\> 18 and \\\u003C 75 years\n2. Heart failure with left ventricular ejection fraction ≤ 35%\n3. Persistent symptoms of heart failure, New York Heart Association class III or IV\n4. Requirement for high-dose diuretic therapy, specifically Furosemide \\> 50 mg\u002Fday orally as per routine clinical practice\n5. At least one of the following additional indicators of severity or refractoriness:\n\n   * need for progressive escalation of diuretics,\n   * intolerance to optimized medical therapy,\n   * persistence of symptoms despite advanced treatments such as (but not limited to) cardiac resynchronization therapy (CRT-D)and\u002For MitraClip\n6. Ability and willingness to provide written informed consent for participation and for the processing of clinical data for research purposes",[13,14],"Drug: GDMT","Other: Quality of life questionnaire",[16,26],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","GDMT","Percentage of patients receiving GDMT in advanced heart failure",[9],[22,23,24,25],"beta-blocker","mineralcorticoid receptor antagonist","SGLT2 inhibitor","renin-angiotensin-aldosterone system drug",{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"Quality of life questionnaire","Absoute Quality of life questionnaire scores (SF 36 questionnaire and EqVAS scale, both validated in Italian language",[9],[31],{"name":32,"affiliation":33,"role":34},"Anna Maria Scandroglio, MD","IRCCS Ospedale San Raffaele","PRINCIPAL_INVESTIGATOR",[36],{"name":32,"role":37,"phone":38,"phoneExt":10,"email":39},"CONTACT","0226437154 \u002F +393473249312","scandroglio.mara@hsr.it",[41,57],{"facility":42,"status":43,"city":44,"state":10,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"ASST Ospedale Papa Giovanni XXIII","NOT_YET_RECRUITING","Bergamo","24127","Italy","IT",{"type":49,"coordinates":50},"Point",[51,52],9.66721,45.69601,{"lat":52,"lon":51},[55],{"name":56,"role":37,"phone":10,"phoneExt":10,"email":10},"Attilio Iacovoni, MD",{"facility":33,"status":58,"city":59,"state":10,"zip":60,"country":46,"countryCode":47,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"RECRUITING","Milan","20132",{"type":49,"coordinates":62},[63,64],9.18951,45.46427,{"lat":64,"lon":63},[67],{"name":32,"role":37,"phone":68,"phoneExt":10,"email":39},"02.26437154 \u002F +393473249312",{"type":34,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Marina Pieri","MD","100636076","evaluating-adherence-to-guideline-directed-medical-therapy-in-patients-with-advanced-heart-failure-100636076",false,"NCT07560982","Evaluating Adherence to Guideline-Directed Medical Therapy in Patients With Advanced Heart Failure","Evaluating Adherence to Guideline- Directed Medical Therapy Using the Four-Pillar Strategy in Patients With Advanced Heart Failure: the Advanced Heart Failure Unified Board (Ad-HUB) Study","ad-HUB","Inclusion Criteria:\n\n1. Age \\> 18 and \\\u003C 75 years\n2. Heart failure with left ventricular ejection fraction ≤ 35%\n3. Persistent symptoms of heart failure, New York Heart Association class III or IV\n4. Requirement for high-dose diuretic therapy, specifically Furosemide \\> 50 mg\u002Fday orally as per routine clinical practice\n5. At least one of the following additional indicators of severity or refractoriness:\n6. need for progressive escalation of diuretics,\n7. intolerance to optimized medical therapy,\n8. persistence of symptoms despite advanced treatments such as (but not limited to) cardiac resynchronization therapy (CRT-D)and\u002For MitraClip\n9. Ability and willingness to provide written informed consent for participation and for the processing of clinical data for research purposes\n\nExclusion Criteria:\n\n1. Age ≤ 18 years or ≥ 75 years\n2. Left ventricular ejection fraction \\> 35%\n3. Mild or absent symptoms (New York Heart Association class I-II)\n4. Good response to optimized conventional guideline-directed medical therapy\n5. Extreme frailty or severe non-reversible disability, or psychiatric or cognitive disorders preventing adherence to follow-up\n6. Pregnant or breastfeeding women","ALL","18 Years","75 Years",{"count":84,"type":85},300,"ESTIMATED","OBSERVATIONAL","A Prospective Observational, Multi-Center, Real-World Pharmacological Study Evaluating Adherence to Guideline-Directed Medical Therapy Using the Four-Pillar Strategy in Patients with Advanced Heart Failure",[89],"Heart Failure",[91,92,93,94],"Medical therapy","Quality of life","Heart failure","mechanical circulatory support","2026-07-01",{"date":97,"type":98},"2026-07-06","ACTUAL",{"date":100,"type":98},"2026-05-08",{"date":102,"type":85},"2036-07-01",{"name":5,"class":6},2]